Company Overview
Snapshot
Founded in April 2014 by Amir Bahar and Nora Nseir, Nurami Medical operates with 11–50 employees. The company has raised $43.65M across 9 funding rounds from 11 investors. In August 2023, Nurami Medical's ArtiFascia® Dura Substitute received FDA clearance, marking a significant regulatory milestone.
Business overview
Nurami Medical specializes in modernizing soft tissue surgical repair through its proprietary electrospun-based platform technology. The company develops innovative biosurgical implants using nanofibers and novel biomaterials to effectively seal and heal wounds. These advanced products aim to address complications associated with current soft tissue implants, such as leaks, while promoting healthy tissue formation, including dura repair. Nurami Medical's flagship product, ArtiFascia, is a multilayer dura repair graft made of biocompatible and bioabsorbable polymers, designed to promote neodura regeneration, and is commercially available in the USA.
Strategic signal
In November 2025, Nurami Medical announced the successful completion of Phase 1 milestones for its EIC-backed grant for the ArtiFix dural repair graft. This indicates continued progress in the development of its regenerative solutions, signaling strong operational execution and potential for future product advancements in the soft tissue repair market.
Log in to access full profile ›Company Intelligence Q&A
- What was a key regulatory achievement for Nurami Medical?
- In August 2023, Nurami Medical's ArtiFascia® Dura Substitute received FDA Clearance, enabling its commercial use in the USA.
- What is the status of Nurami Medical's EIC-backed grant?
- In November 2025, Nurami Medical announced the successful completion of Phase 1 milestones in its EIC-backed grant for the ArtiFix Dural Repair Graft.
- Who was appointed Chairman of Nurami Medical?
- In May 2022, Peter Stebbins was appointed Chairman of Nurami Medical.